Last reviewed · How we verify
Welbutrin XL
Wellbutrin XL is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the neuronal synapse.
Wellbutrin XL is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the neuronal synapse. Used for Major depressive disorder, Seasonal affective disorder, Smoking cessation (off-label use).
At a glance
| Generic name | Welbutrin XL |
|---|---|
| Also known as | Buproprion XL |
| Sponsor | Massachusetts General Hospital |
| Drug class | Norepinephrine-dopamine reuptake inhibitor (NDRI) |
| Target | Norepinephrine transporter (NET) and dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting the reuptake of norepinephrine and dopamine, Wellbutrin XL allows these neurotransmitters to remain active longer in the synaptic space, enhancing their signaling. This mechanism differs from selective serotonin reuptake inhibitors (SSRIs) and is thought to improve mood, motivation, and energy. The extended-release formulation provides sustained drug levels throughout the day.
Approved indications
- Major depressive disorder
- Seasonal affective disorder
- Smoking cessation (off-label use)
Common side effects
- Insomnia
- Dry mouth
- Nausea
- Headache
- Dizziness
- Seizures
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Welbutrin XL CI brief — competitive landscape report
- Welbutrin XL updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI